The antibody drug conjugate conferred a significant, though modest, improvement in overall survival compared with chemotherapy in patients with HR+ and HER2− disease.
In a prior analysis of the industry-funded, international, randomized, open-label, phase 3 TROPiCS-02 trial, sacituzumab govitecan (SG) — a Trop-2–directed antibody–drug conjugate approved for the treatment of triple-negative metastatic breast cancer — conferred a significant improvement in progression-free survival compared with traditional single-agent chemotherapy in patients with endocrine-refractory HR+ and HER2− metastatic breast cancer (J Clin Oncol 2022; 40:3365).
Now, investigators report results of the protocol-specified final analysis of overall survival (OS) and other secondary endpoints of TROPiCS-02. The trial included 543 women (median age, 56; 90% white) who had received at least one previous endocrine therapy, a taxane, a CD…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)